Candida albicans is the most frequent causative agent of candidiasis, now the third-to-fourth most common infection in hospitals in the US and worldwide, and this opportunistic fungus represents an increasing threat to an ever expanding population of immune- and medically-compromised patients. Candidiasis carries unacceptably high mortality rates, about 30-60%, clearly indicating that current antifungal therapy is still ineffective, due to the limited armamentarium of antifungal agents, the toxicity displayed by some of the current therapies, and the emergence of resistance to most classes of antifungals. Moreover, there are no new effective drugs in sight, and the antifungal pipeline is mostly dry. The ability to form biofilms, microbial communities attached to surfaces, is intimately linked to the pathogenesis of C. albicans, and indeed the majority of manifestations of candidiasis are associated with biofilm formation, which further complicates treatment. As such biofilm formation represents a high value target for the development of novel antifungals. Most recently, we have carried out high content screens and identified small molecule compounds that specifically inhibit C. albicans biofilm formation. We have been developing some of these compounds as novel antifungals, having confirmed their potent biofilm-inhibitory activity, lack of toxicity and efficacy in vivo using relevant animal models of candidiasis. The main goal of the current project is to further advance the development of the current leading chemical series of compounds, for which we propose three specific objectives. i) Medicinal Chemistry. We will engage on a focused and systematic medicinal chemistry campaign to advance 3-4 structurally diverse lead chemical series in parallel, establish structure- activity relationships that improve biofilm inhibition properties while also improving physical chemical drug-like properties. ii) In vivo efficacy. We will test a discrete number of compounds within each chemical series in the murine model of hematogenously disseminated candidiasis, as well as in the murine models of catheter- associated candidiasis and oral candidiasis, both of which are associated with biofilm formation. iii) Insights into mechanisms of action, potential for resistance development, and further in vitro characterization. We will perform further characterization of representative compounds of each chemical series showing the most promise in animal models. These will include RNA-Sequencing and screening of mutant collections to gain insights into the molecular target(-s) and mechanism(-s) of action, serial passage assays to evaluate potential development of resistance, combination with current antifungals, as well as in vitro safety pharmacological profiling for determination of off-target activities.

Public Health Relevance

This proposal constitutes a novel approach for the prevention and treatment of candidiasis, which remains one of the most common fungal infections. We propose the development of antifungal drugs with new chemical structures and mode of action, which is inhibition of biofilm formation. Results should ultimately lead to substantial decreases i morbidity and mortality associated with these infections, while simultaneously reducing healthcare costs.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI119554-03
Application #
9276482
Study Section
Drug Discovery and Mechanisms of Antimicrobial Resistance Study Section (DDR)
Program Officer
Franceschi, Francois J
Project Start
2015-06-22
Project End
2020-05-31
Budget Start
2017-06-01
Budget End
2018-05-31
Support Year
3
Fiscal Year
2017
Total Cost
$367,500
Indirect Cost
$117,500
Name
University of Texas Health Science Center San Antonio
Department
Biology
Type
Schools of Arts and Sciences
DUNS #
800189185
City
San Antonio
State
TX
Country
United States
Zip Code
78249
Romo, Jesus A; Pierce, Christopher G; Esqueda, Marisol et al. (2018) In Vitro Characterization of a Biaryl Amide Anti-virulence Compound Targeting Candida albicans Filamentation and Biofilm Formation. Front Cell Infect Microbiol 8:227
Vila, Taissa; Lopez-Ribot, Jose L (2017) Screening the Pathogen Box for Identification of Candida albicans Biofilm Inhibitors. Antimicrob Agents Chemother 61:
Pierce, Christopher G; Vila, Taissa; Romo, Jesus A et al. (2017) The Candida albicans Biofilm Matrix: Composition, Structure and Function. J Fungi (Basel) 3:
Romo, Jesus A; Pierce, Christopher G; Chaturvedi, Ashok K et al. (2017) Development of Anti-Virulence Approaches for Candidiasis via a Novel Series of Small-Molecule Inhibitors of Candida albicans Filamentation. MBio 8:
Vila, Taissa; Romo, Jesus A; Pierce, Christopher G et al. (2017) Targeting Candida albicans filamentation for antifungal drug development. Virulence 8:150-158
Srinivasan, Anand; Torres, Nelson S; Leung, Kai P et al. (2017) nBioChip, a Lab-on-a-Chip Platform of Mono- and Polymicrobial Biofilms for High-Throughput Downstream Applications. mSphere 2:
Montelongo-Jauregui, Daniel; Srinivasan, Anand; Ramasubramanian, Anand K et al. (2016) An In Vitro Model for Oral Mixed Biofilms of Candida albicans and Streptococcus gordonii in Synthetic Saliva. Front Microbiol 7:686
Uppuluri, Priya; Lopez-Ribot, Jose L (2016) Go Forth and Colonize: Dispersal from Clinically Important Microbial Biofilms. PLoS Pathog 12:e1005397
Lara, Humberto H; Romero-Urbina, Dulce G; Pierce, Christopher et al. (2015) Effect of silver nanoparticles on Candida albicans biofilms: an ultrastructural study. J Nanobiotechnology 13:91
Vila, Taissa Vieira Machado; Chaturvedi, Ashok K; Rozental, Sonia et al. (2015) In Vitro Activity of Miltefosine against Candida albicans under Planktonic and Biofilm Growth Conditions and In Vivo Efficacy in a Murine Model of Oral Candidiasis. Antimicrob Agents Chemother 59:7611-20